HomeMarkets Markets In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients By news November 12, 2023 0 310 FacebookTwitterPinterestWhatsApp Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected149,469FansLike396,312FollowersFollow2,650SubscribersSubscribe Latest Articles Charts PSW’s Weekly Webinar: The State of the Markets Report (2/25/2026) Markets Trump Orders Government to Stop Using Anthropic After Pentagon Standoff Markets Fall Back Friday – February Ending on a Week Note? Markets AI “hot takes” are becoming a market risk Markets How Trump’s renewed tariff chaos will stifle investment around the world Market News Netflix Backs Out of Bid for Warner Bros., Paving Way for an Ellison Takeover AI Anthropic Takes a Stand Markets A Modest Proposal For Solving the AI Energy Crisis Markets Thursday Thrust: One Stock to Rule Us All (NVDA, of course!) AI AI’s growing appetite for power is putting Pennsylvania’s aging electricity grid to the test Markets Epstein Files Are Missing Records About Woman Who Made Claim Against Trump Market News Violent aftermath of Mexico’s ‘El Mencho’ killing follows pattern of other high‑profile cartel hits AI Nvidia’s Quarterly Profit Hits $43 Billion on Strong A.I. Chip Sales Markets ⚡ Powering the AI Boom: Data Centers and Ratepayer Protection Pledge (SCAM!!!) Load more